Business Context and Reporting Period
Company: Actuate Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date: November 12, 2024
Context: The Company is an emerging growth company incorporated in Delaware. This filing reports a material regulatory development regarding its product candidate, elraglusib.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
Regulatory Milestone: On November 12, 2024, the Company received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration (FDA) for its product candidate elraglusib.
Indication: The designation is for the treatment of Ewing sarcoma.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) announcing the FDA designation. No specific financial guidance or operational outlook is provided in this document.
Risks and Contingencies: The filing notes that the information contained in Item 7.01 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific benefits of the Rare Pediatric Disease Designation for elraglusib in the treatment of Ewing sarcoma.
- Review the full text of the press release (Exhibit 99.1) for details on the development timeline and potential market impact.
- Check subsequent filings (e.g., 10-Q or 10-K) for the Company's current cash position and runway, as this 8-K contains no financial data.
- Confirm the status of ongoing clinical trials for elraglusib to assess the likelihood of future regulatory approvals.